Document is current

Article History

Received: 3 October 2024

Accepted: 28 February 2025

First Online: 12 March 2025

Declarations

:

: This study involves human participants enrolled through ALLFTD (NCT04363684), and was approved by the Johns Hopkins Medicine Institutional Review Board (IRB) serving as the single IRB for the ALLFTD Consortium (CR00042454/IRB00227492). Participants or their caregivers provided written informed consent.

: B.S.A. receives research support from the Centers for Disease Control and Prevention, the National Institutes of Health (NIH), Ionis, Alector and the CJD Foundation. He has provided consultation to Acadia, Ionis and Sangamo.B.F.B. has served as an investigator for clinical trials sponsored by Alector, Transposon, EIP Pharma and Cognition Therapeutics. He serves on the Scientific Advisory Board of the Tau Consortium which is funded by the Rainwater Charitable Foundation. He receives research support from NIH.A.L.B. receives research support from the NIH, the Tau Research Consortium, the Association for Frontotemporal Degeneration, Bluefield Project to Cure Frontotemporal Dementia, the GHR Foundation and the Alzheimer’s Association. He has been a consultant for Alchemab, Alector, Alexion, Amylyx, Arrowhead, Arvinas, Eli Lilly, Muna, Neurocrine, Ono, Oscotec, Pfizer, Switch, Transposon, and UnlearnAI.A.C.B. receives research support from the NIH, Cognition Therapeutics and EIP Pharma, serves as a consultant for Creative Biopeptides and Cognition Therapeutics, and serves on the data safety management board of AviadoBio Pharma.B.C.D. is a consultant for Acadia, Alector, Arkuda, Biogen, Denali, Eisai, Genentech, Ilios, Lilly, Merck, Takeda, Wave Lifesciences. He also receives royalties from Cambridge University Press, Elsevier, Oxford University Press.K.D.-R. receives research support from the NIH and served as an investigator for a clinical trial sponsored by Lawson Health Research Institute.T.M.F. receives research support from the NIH.D.R.G. received research funding from the NIH and the Michael J Fox Foundation, served as a paid consultant for Eisai, Fujirebio and GE Healthcare, and serves on a DSMB for Artery Therapeutics.T.F.G. receives research support from the NIH, and is a member of the Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium.N.R.G.-R. receives royalties from UpToDate and has participated in multicenter therapy studies by sponsored by Biogen, Eisai, and Lilly. He receives research support from the NIH.I.M.G. served as a site investigator for trials sponsored by Alector, Eisai and Biogen. For some trials for which he was site PI, he received funding from the NIH.C.M.H. is a site principal investigator or sub-investigator for several industry (Alector, Janssen, Biogen, Cogito Tx) sponsored clinical trials with funding through Emory Office of Sponsored Programs and receives funding from NIH.M.G.H. is on the Molecular Neurodegeneration editorial board.H.W.H. receives funding from NIH.G.-Y.R.H. has served as an investigator for clinical trials sponsored by Biogen, Cassava, and Eli Lilly. He receives research support from the Canadian Institutes of Health Research and the Alzheimer Society of British Columbia.E.D.H. receives research support from the NIH (R01AG062268, R01MH120794, U01AG79850).D.I. receives research support from the NIH, as well as Prevail, Passage Bio, Alector and Denali.J.Y.K receives research support from the Intramural Research Program, NINDS, NIH.I.L. is supported by the National Institutes of Health grants: U01NS100610, U01NS80818, R25NS098999; U19 AG063911-1, 1R21NS114764-01A1 and 2 P30 AG062429-06; the Michael J Fox Foundation, Parkinson Foundation, Lewy Body Association, CurePSP, Roche, Abbvie, Biogen, Lundbeck, EIP-Pharma, Novartis, Alterity and UCB. She is a Scientific advisor for Amydis (gratis), Aprinoia, and Rossy Center for Progressive Supranuclear Palsy University of Toronto. She receives her salary from the University of California San Diego and as Chief Editor of Frontiers in Neurology.I.R.M. receives research funding from the Canadian Institutes of Health Research, the Alzheimer’s Association US, the NIH and the Weston Brain Institute.J.C.M. receives grant support from the NIH, and participates in clinical trials sponsored by Biogen and Alector.N.G. has participated or is currently participating in clinical trials of anti-dementia drugs sponsored by Bristol Myers Squibb, Eli Lilly/Avid Radiopharmaceuticals, Janssen Immunotherapy, Novartis, Pfizer, Wyeth, SNIFF (The Study of Nasal Insulin to Fight Forgetfulness) and the A4 (The Anti-Amyloid Treatment in Asymptomatic Alzheimer’s Disease) trial. She receives research support from Tau Consortium and the Association for Frontotemporal Dementia and is funded by the NIH. She serves as a consultant for the Blue Cross Blue Shield Association.LÖ received funding from the Swedish Dementia Foundation.C.U.O. has received research funding from the NIH, Lawton Health Research Institute, National Ataxia Foundation, Alector and Transposon. He is also supported by the Robert and Nancy Hall Brain Research Fund, the Jane Tanger Black Fund for Young-Onset Dementias and a gift from Joseph Trovato. He is a consultant with Alector Inc., Acadia Pharmaceuticals, Reata Pharmaceuticals, Otsuka Pharmaceuticals, Lykos Therapeutics, and Zevra Therapeutics. He serves of the scientific advisory boards of the Tau Consortium and the FTD Disorders Registry.B.P. receives grant support from the NIH, and participates in clinical trials sponsored by Alector.L.P. receives grant support from the NIH and the Association for Frontotemporal Degeneration, and has provided consultation to Expansion Therapeutics.P.S.P. receives research funding from the NIH and has received research support from the Doris Duke Fund to Retain Clinical Scientists.R.R. receives research funding from the NIH and the Bluefield Project to Cure Frontotemporal Dementia. She is on the scientific advisory board of Arkuda Therapeutics and receives royalties from progranulin-related patent. She is also on the scientific advisory board of the Foundation Alzheimer.E.M.R. receives research support from the NIH.E.D.R. has received research support from the NIH, the Bluefield Project to Cure Frontotemporal Dementia, the Alzheimer's Association, the Alzheimer's Drug Discovery Foundation, the BrightFocus Foundation, and Alector; has served as a consultant for AGTC and on a data monitoring committee for Lilly; and owns intellectual property related to tau.H.J.R. has received research support from Eisai Pharmaceuticals and Genentech, and receives research support from the NIH and the state of California.W.W.S has received consulting fees from BridgeBio, Guidepoint Global, Inc., and GLG Council; speaker honoraria from Verge Genomics; and compensation as a member of the scientific advisory board for Lyterian Therapeutics.M.C.T. has served as an investigator for clinical trials sponsored by Biogen, Avanex, Green Valley, Roche/Genentech, Bristol Myers Squibb, Eli Lilly/Avid Radiopharmaceuticals and Janssen. She has served as a consultant for Eli Lilly, and Eisai Pharmaceuticals. She has received research support from Hoffman-Roche. She receives research support from the NIH, Weston Brain Foundation, CurePSP.R.R.D, D.W.D, K.M.F., L.K.F, A.L.L., L.J.W, M.F.M, U.S. and A.S. have nothing to disclose.